My watch list  

Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.

More about TranScrip Partners
  • News

    TranScrip Partners expands further with two new senior appointments

    TranScrip Partners LLP announced the appointment of two new senior partners, Julia Lloyd-Parks and Mark Watling. The move is set to further enhance the organisation’s high level expertise in clinical research, clinical development and medical affairs across multiple therapeutic areas. Thi ... more

    TranScrip Partners appoints David Oxlade as Chairman of the Board

    TranScrip Partners LLP, a pharmaceutical development company providing expert advice and hands-on support to pharmaceutical and biotechnology companies across a wide range of therapeutic areas, announced the appointment of David Oxlade to the position of Chairman of the Board. David Oxlad ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE